awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q34765364-C84000A3-3338-408D-B9F7-206E0CE3FE38
Q34765364-C84000A3-3338-408D-B9F7-206E0CE3FE38
BestRank
Statement
http://www.wikidata.org/entity/statement/Q34765364-C84000A3-3338-408D-B9F7-206E0CE3FE38
A perspective on vascular disrupting agents that interact with tubulin: preclinical tumor imaging and biological assessment
P2860
Q34765364-C84000A3-3338-408D-B9F7-206E0CE3FE38
BestRank
Statement
http://www.wikidata.org/entity/statement/Q34765364-C84000A3-3338-408D-B9F7-206E0CE3FE38
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
dca3bc682f2d7dddac2f80fb9d8213bc039da4a8
P2860
FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer.